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SUMMARY
We undertook a representative survey of measles antibodies in Addis Ababa, Ethiopia 1994,
to characterize immunity and transmission. Speciﬁc-antibody levels (IU/l) were determined by
ELISA for 4654 sera from individuals aged 0–49 years (1805<15 years) collected by stratiﬁed
household-cluster sampling. The proportion seronegative (<100 IU/l) was 20% (95% CI: 16–25)
in children 9–59 months old, declining to 9% (7–12) in 5–9 year olds, 5% (4–7) in 10–14 year
olds, and<1% in adults. The proportion of children (<15 years old) with low-level antibody
(100–255 IU/l) was 8% (7–10). Vaccination and an absence of a history of measles illness were
strongly associated with low-level antibody. History of measles vaccination in 9 months to
14-year-old children wasy80%. We estimate a primary vaccine failure rate of 21% (12–34) and
continued high measles incidence of 22 per 100 susceptibles (19–24) per annum. Our data support
the introduction of campaign vaccination in the city in 1998, although higher routine vaccine
coverage is required to sustain the impact. The implications of a high prevalence of low-level
antibody are discussed.
INTRODUCTION
Serological surveys of speciﬁc antibody status in
vaccinated populations provide valuable information
to health authorities on the impact of the intervention
on continued transmission [1, 2], the distribution
(by age and geographical location) of proportions
seronegative [3–5], the risks of an outbreak [1, 6], and
the progress towards elimination [7]. Surveys that re-
port on the level of detectable antibody, rather than
presence or absence, may further inform on the likely
distribution of sub-clinical, mild and typical measles
re-infection and on the potential for community per-
sistence of measles [3, 4, 8–10].
There is little recent data on measles seroepi-
demiology and the impact of vaccination on measles
transmission in Ethiopia [11, 12] or elsewhere in much
* Author for correspondence : Welcome Trust Research Labs,
Kenya Units, PO Box 230, Kiliﬁ, Kenya.
Epidemiol. Infect. (2003), 130, 507–519. f 2003 Cambridge University Press
DOI : 10.1017/S0950268803008446 Printed in the United Kingdom
of Africa. Here we report on a large representative
survey of measles speciﬁc antibodies in Addis Ababa,
in 1994, following over a decade of moderately high
coverage of routine measles vaccination (y80%) and
prior to the implementation of measles immunization
campaigns. The aim of the study was to characterize
in detail measles speciﬁc-immunity and transmission
within a vaccinated urban developing country popu-
lation, and assess the implications of the results for
measles control by vaccination.
METHODS
Survey details
Emphasis is placed on details not presented in pre-
vious related publications [13–15]. Ethical approval
was obtained from authorities in Ethiopia (Ethical
Committee of the Ethiopian Health and Nutrition
Research Institute) and the United Kingdom (St
Mary’s Research Ethics Committee, London Univer-
sity).
Setting
Addis Ababa is the capital city of Ethiopia situated on
a high plateau (altitude approximately 2000 m), with
an urban population of 2.1 m [16] and adminis-
tratively organized into urban dwellers associations or
kebeles (each of roughly 1500–2000 registered house-
holds [16]). The expanded programme on immuniz-
ation (EPI) was introduced in Ethiopia in 1980,
targeting children under 2 years of age, then from
1986 under 1 year [17], with a single measles dose at
the World Health Organization’s recommended age
of 9 months. Data on measles vaccination coverage in
Addis Ababa is unavailable for the 1980s, and oﬃcial
ﬁgures between 1992/3 and 1993/4 give the proportion
under 1 year of age vaccinated at around 75–80%
(Addis Ababa City Administration Health Bureau,
personal communication). A measles campaign tar-
geting children aged 9–59 months was conducted in
nine cities in Ethiopia, including Addis Ababa, in
November 1998, as part of the accelerated measles
control strategy in Ethiopia [18].
Survey design and implementation
A stratiﬁed cluster-sampling survey design was adop-
ted in which 35 households (15% non-compliance
assumed) were selected at random (from oﬃcial regis-
ters) within each of 20 kebeles in the inner city (high
density stratum) and 20 kebeles in the outer city,
selected with probability proportional to estimated
size. Sample size calculations, using standard methods
and an assumed cluster sampling design eﬀect of
2 [19], determined a minimum requirement of 150
samples for each age class (deﬁned as single years up
to age 4 years, and 5 year classes from 5–9 to 45–49
years) to provide acceptable precision of preva-
lence estimates, ie 95% conﬁdence intervals (CI) of
¡7–12%.
Households were visited between end of May and
early October of 1994. A letter from the Health
Bureau of Region 14 (Addis Ababa) was provided
to oﬃcials of each selected kebele and to each house-
hold head informing of the nature of the study. If
consentwas given an interviewwas carried outwith the
head of the household by trained interviewers, elicit-
ing detail on household socio-demography and socio-
economics. Additionally, information was obtained
on measles vaccine history for children <15 years of
age [categorized as (i) positive card record of vacci-
nation, (ii) positive history without card, (iii) negative
card record or else, respondent negative, or (iv) re-
spondent does not know] and past measles [categor-
ized as (i) yes (ii) no or (iii) unknown] for all ages
based upon recognition of classical symptoms. A
blood sample was requested from all children under
age 5 years, and adults aged 15–49 years, and from 1
in 2 of children aged 5–14 years by random selection.
Up to two revisits were made if household members
were previously unavailable. Sera were stored at
x20 xC.
Screening methods
Serum samples were screened by a commercial EIA
kit for measles-speciﬁc IgG antibodies (Rubeola G,
Gull Laboratories, Atlas Bioscan Ltd, Bognor Regis,
UK) [21] following the manufacturer’s instructions,
with calibration using a measles international stan-
dard allowing quantiﬁcation of results in IU/l [4, 21].
Data processing and analysis
Data was double entered onto Epi-Info [22], with
internal range checks, and later compared for con-
sistency checking and cleaned.
Classiﬁcation of measles antibody status
Based on the frequency distribution of (log) antibody
levels in unvaccinated individuals, we deﬁned as
seronegative individuals whose measles-speciﬁc IgG
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antibody level were less than 100 IU/l. Seropositive
individuals were stratiﬁed by cut-oﬀ levels of 255 [4],
500 [7] and 1000 IU/l [9].
Statistical analysis
Data were analysed using the statistical software
STATA (Statacorp, v. 6.0, 1999, College Station, TX,
USA) applying speciﬁc survey procedures (‘svy’
commands) that account for survey design. The
kebele was deﬁned as the primary sampling unit, and
probability weights were applied to account for un-
equal cluster and stratum population sizes (details of
which are described elsewhere [13, 15]). Within these
survey procedures, hypothesis testing uses the ad-
justed Wald test and Pearson’s design-based x2 test.
Logistic regression (STATA svylogit command) was
used to identify independent risk factors associated
with measles seronegative status or with low sero-
positive status (100–255 IU/l). Variables identiﬁed
as signiﬁcant (P<0.05) in univariate analysis were
included in a multivariate model, followed by a step-
down procedure to remove those factors not con-
tributing signiﬁcantly (P<0.05).
Estimation of measles incidence
Seroprevalence data were analysed with the aim of
estimating the force of infection acting on susceptibles
(the per susceptible incidence rate) in a population
with a vaccination programme in place. It is assumed
that the proportion susceptible to infection at age
a, x(a), is accurately deﬁned by the proportion
seronegative in the serological survey. Analysis is
conﬁned to the age group below 15 years for which
vaccination data was collected, and above which there
is little observable change in seroprevalence. The
estimation procedure makes the key simplifying as-
sumption that the eﬀect on seroprevalence of measles
vaccination has been constant over the time-span of
interest (1980–94), which appears reasonable from
coverage data from oﬃcial Addis Ababa sources
and this survey. Changes, with age, in the propor-
tion seronegative are assumed to be the result of
measles transmission, the rate of which potentially
varies both by age (diﬀerences in social mixing) and
through time (as vaccination acts to reduce the rate
of transmission). These factors are investigated. Age-
prevalence of seronegativity may be aﬀected by mi-
gration into the city, which we control for in the
analysis. The method makes the further simplify-
ing assumptions that all individuals seroconvert upon
primary infection, measles associated mortality is
negligible, and positive seroprevalence is not dimin-
ished by waning of antibody (whether vaccine- or
wild-type induced) in the age group of interest (<15
years).
On this basis we estimated the force of measles in-
fection using a piece-wise constant (PWC) catalytic
infection model [13, 23] using year group data for ages
1–14 years. The force of infection is assumed constant
within an age class i, li, but can vary between age
classes i=1, m, hence the proportion susceptible pre-
dicted by the model, xk(a)
x0(a)=x0(aix1) exp [xli(axaix1)], (1)
where i is such that aix1fafai, and lio0. The as-
sumption is of an exponential decay in the proportion
susceptible between age aix1 and a due to an age-band
speciﬁc constant force of infection, li. We avoid ex-
plicitly deﬁning the rate of loss of maternal antibody
and the eﬀect of vaccination in the ﬁrst year of life by
setting an initial condition for the proportion suscep-
tible at age 0, xk(0). xk(0) and li, i=l, m, were par-
ameters to be estimated from the data, which we did by
maximum likelihood, and estimated 95% conﬁdence
limits assuming an approximate x2 distribution of the
log-likelihoods [24]. The constrained model assumes a
constant force of infection over all ages (1–14 years).
We explored a reduction in the age range used for
parameter estimation (i.e. upper age of 10 or 5 years).
To determine the presence of time (or age) dependent
variation in the force of infection, the model ﬁt using
2 or 3 age bands (1–5, 6–10 and 11–14 years, or com-
bination therein) was assessed using the likelihood
ratio test [25].
RESULTS
Survey population characteristics
Individuals numbering 8638 from 1384 households
were registered in the study, 53% in the inner city, with
7.2% aged under 5 years, 32.5% under 15 years and
10.2% aged 50+ years. The age distribution closely
reﬂected that reported in the 1994 census of Addis
Ababa: 8.0% <5 years, 31.6% <15, 8.5% 50+
(tabulated details are given elsewhere [15, 16]), and
shows that the per cent less than 5 years of age was
signiﬁcantly less than in 1984 (12.4%) [20]. The over-
all male : female ratio was 46.3:53.7% with relatively
more females than in the 1994 census (48.4:51.6%).
For other characteristics for which comparison was
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possible, we found close agreement with the cen-
sus : average household size (de jure population)
5.3 (census 5.5), non-migrants (resident o10 years)
87% (census 80%), literacy level 83% (census 83%),
and ethnicity, 49% Amharas (49%), 17% Oromos
(19%), 9% Tigre (8%), 19% Gurage (18%). No sig-
niﬁcant diﬀerence was found between the inner and
outer city age distribution, but there was a higher
proportion of females in the inner city (55 vs. 52%,
P=0.0112).
From 1384HHs surveyed, 1341 (97%) included one
or more individuals of eligible age (i.e.<50 years), of
which 1262 (94%) contained at least one individual
who gave a blood sample. For the 79 (6%) HHs who
refused to give blood, there was no signiﬁcant diﬀer-
ence (P>0.05) in inner:outer city distribution or
distribution by age, sex, ethnicity, educational cat-
egory, or migrant status, of heads of household,
compared with respondent households, but a signiﬁ-
cantly lower number of persons per household in the
non-respondent households (P=0.01). Of the 7735
individuals aged <50 years in the 1341 eligible HHs,
4763 (62%) provided a blood sample. A higher
proportion of females gave blood (2852/4195, 68%
females, vs. 1911/3540, 54% males, P<0.001). There
was no marked diﬀerence by age in the propor-
tion of females giving blood, however, for males, the
proportion declined from 74% in 0–4 year olds, to
63% in 5–14 year olds, to 47% in adults 15–49 years
of age. The distribution by age of this sub-sample
providing a blood specimen follows closely the pattern
in the 1994 census and the total registered sample,
although with an under-representation of adult males
(male: female ratio for adults 15–49 years in the
sample is 21.2:40.0% and the census is 31.3:34.2%
[16].
For 109 out of the 4763 individuals aged 0–49 years
who gave blood, there was insuﬃcient serum residue
for measles antibody determination. We present re-
sults of analyses of measles serological data on 4654
individuals aged <50 years (1805 aged <15 years)
arising from 1257 households in 40 kebeles.
Age-prevalence of measles antibodies
Over all ages, the estimated prevalence of sero-
negatives (i.e. with antibody levels <100 IU/l), with
no account taken of sampling structure (i.e. assuming
simple random sampling), was 4.1%. Adjusting for
the survey design the estimate was little changed at
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Fig. 1. Age-distribution of measles-speciﬁc antibody levels in Addis Ababa, 1994. The proportions (%) seronegative (anti-
body levels <100 IU/l, black bars), with low-level antibody (100–255 IU/l, dark grey bars), or with levels of 255–500 IU/l
(light grey), or 500–1000 IU/l (open bars), are shown for each age class. Geometric mean titre (GMT) of measles antibody
(seropositives only) is shown by the continuous line (measured on the right vertical axis). The median age of classes 0–11
months, 1, 2, … 14 years, 15–19, and 20–29 to 40–49 years are shown and have the corresponding sample sizes : 55, 69, 69,
100, 124, 108, 90, 141, 125, 145, 175, 114, 178, 155, 157, 890, 985, 599, 375 (total 4654).
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4.0% (95% CI 3.4–4.7). We estimate a design eﬀect
(ratio of variances for cluster and random sampling)
of 1.19. Figure 1 shows the estimated age-stratiﬁed
prevalence of diﬀerent levels of measles-speciﬁc anti-
body in the population. Seronegative prevalence de-
creased from 66% (95% CI 46–82) in infants less
than 9 months of age (n=33), to 20.4% (16.3–25.1) in
9–59 month olds, 4.9% (3.6–6.6) in 5–14 years olds,
and 0.7% (0.4–1.2) in adults (15–49 years). The cor-
responding estimated proportions of the population
with low level antibody (100–255 IU/l) were 11.2%
(4.2–26.4), 13.3% (11.1–15.9), 6.6% (5.3–8.3) and
1.2% (0.9–1.6). The proportion of children under 15
years old who were seronegative, or had antibody
levels (IU/l) of 100–255, 255–500 or 500–1000, was
9.3% (7.0–10.9), 8.1% (7.5–10.4), 8.7% (7.2–10.5)
and 22.9% (19.0–27.4), respectively. In the age classes
9–59 months and 5–14 years, the proportion of sero-
positives with low level antibody (100–255 IU/l) was
16.7% (13.8–20.2) and 7.0% (5.5–8.7), respectively.
Geometric mean titre (GMT) of measles antibody in
seropositives (antibody level o100 IU/l) increased
with age to a maximum in age class 15–19 years (Fig.
1, line). In the age group 15–49 years the antibody
proﬁle showed little change. Note that above 14 years
of age very few individuals will have had measles
vaccination.
The reported vaccination status of children
The distribution by age in the reported vaccination
status of children aged 9 months to 14 years, i.e.
‘vaccine-eligible ’ (VE) group, is shown in Figure 2.
The age at vaccination was not recorded. Not shown
are the results for 33 infants aged less than 9 months
of which 29% (95% CI 15–49) had a history of vac-
cination (documented by card or a verbal history),
19% by card alone. For 9–23 months old the pro-
portion with vaccination history was 81% (95% CI
71–89) or with card alone was 42% (33–51). With
increasing age there was a marked decline in the pro-
portion with a card record of measles vaccination to
under 10% in children aged greater than 9 years old,
whereas the proportion with vaccination history was
relatively stable (79%, range 68–88) over the age
range 9 months to 14 years. The proportion whose
vaccine status was unknown increased with age from
2% in 9 to 23-month-old children to 15% in 14 year
olds. Excluding these individuals of unknown status,
the overall proportion of VE children with a history
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Fig. 2.Distribution of measles vaccine status in Addis Ababa, 1994, in children aged 9–11 months to 14 years, categorized as
(a) vaccination veriﬁed by card (dark grey, 15%, n=274), (b) verbal history of vaccination (medium grey, 64%, n=1114),
(c) unvaccinated (light grey, 14%, n=246) and (d ) unknown (white, 7%, n=134). Sample sizes corresponding to the age
group 9–11 months and yearly age groups 1–24 years are as follows : 22, 69, 69, 100, 123, 107, 90, 141, 125, 144, 175, 114, 178,
155, 156 (33 were aged 0–8 months, and vaccine data were missing for 4 others.)
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Table 1. Univariate analysis of potential factors associated with measles seronegative status (<100 IU/l ) or
low seropositive status (100–255 IU/l ) in vaccine eligible (VE ) children (9 months to 14 years of age) in
Addis Ababa, 1994
Variable
Seronegative status Low seropositive status*
n % P n % P
Age (years)
1–4 384 20.4 0.000 305 16.7 0.000
5–9 609 7.43 563 9.42
10–14 779 2.91 756 5.15
Sex
M 828 9.34 0.116 760 11.6 0.197
F 934 7.2 864 9.91
History of measles
Yes 779 2.56 0.000 759 5.32 0.000
No 786 12.3 688 13.3
Unknown 206 14.1 176 5.82
Vaccination status
Vaccine/card 274 7.75 0.0485 252 13.8 0.000
Vaccine/history 1114 6.57 1042 9.27
Unvaccinated 246 15.4 207 3.56
Unknown 134 10.1 119 2.42
Stratum#
Inner 882 6.88 0.063 821 5.45 0.000
Outer 890 9.90 801 13.1
Length of residence
All life 1538 7.52 0.031 1420 9.40 0.016
Migrant$ 234 12.76 204 4.41
Ethnic group
Amhara 825 7.84 0.681 758 8.74 0.183
Oromo 299 10.9 266 12.3
Tigre 167 6.56 156 6.39
Gurage 364 8.08 335 6.87
Other 111 7.19 103 10.7
Household size
<5 171 10.2 0.233 150 7.30 0.800
5–9 1075 8.71 980 9.14
10+ 526 6.47 492 8.52
Number sleeping in same room
f2 219 7.54 0.815 202 7.46 0.473
3–5 943 8.65 859 9.75
o6 608 7.80 561 7.61
Education
None 269 11.4 0.371 238 9.07 0.725
Read and write 494 6.67 460 8.92
1–6 years 399 7.26 369 7.04
7–12 years 427 8.83 389 8.92
>12 years 183 7.99 168 11.5
Ownership of house
Rent/other 1091 7.40 0.178 1007 7.62 0.044
Own 670 9.67 607 10.8
Type of wall
Wood, bamboo, canvass 1604 8.42 0.341 1467 8.30 0.060
Bricks/stone 163 6.18 152 13.6
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of vaccination was 85% (95% CI 82–88) and did
not diﬀer by age (P=0.1404). No diﬀerence was ob-
served between inner and outer city in vaccination
prevalence, and in all clusters exceeded 65%. A sig-
niﬁcantly higher fraction of lifelong residents of
Addis Ababa had a history of vaccination relative
to migrants (not born in Addis Ababa) (86 vs. 33%,
P<0.0001).
Vaccine failure rate and failure of vaccination
Of children aged 9–23 months with history of measles
vaccination 21% (95% CI 12–34) were seronegative
(with no diﬀerence in seronegative prevalence be-
tween those with cards or verbal history). This result
is unaﬀected if we exclude migrants. In the total VE
group (9 months to 14 years) 8.4% were identiﬁed as
seronegative (Fig. 1), of which 14.3% (9.4–21.3) had
card evidence, and 50.8% (39.3–62.3) verbal history,
of measles vaccination. In seronegatives aged 9–23
months 41% (18–69) had card evidence and 42%
(18–69) had verbal history of vaccination.
Relationship between history of measles, measles
vaccination and seroprevalence
For each person we recorded his/her history of
measles-like illness (deﬁnitions : yes, no, did not
know), the condition well known locally as Kufugn.
The proportion with a reported measles-like episode
was 43% in children under 15 years of age and 55%
of adults 15–49 years old, and did not diﬀer between
city strata. In the VE group the proportion with a
history of measles was marginally lower in those
with card evidence of vaccination (33%) than those
reportedly unvaccinated (43%) (P=0.116).
The reliability of a reported history of measles was
assessed in 212 individuals of the VE group who were
reported as unvaccinated (here we are assuming
reported absence of vaccination is reliable). We ex-
cluded individuals with unknown history of measles.
Of 182 measles seropositive individuals 103 reported
a measles history (sensitivity of 57%), and 27 out of
30 seronegatives had no history of measles (speciﬁcity
of 90%). Thus we had few false positive reports of
Table 1. (cont.)
Variable
Seronegative status Low seropositive status*
n % P n % P
Type of roof
Corregated iron 1728 8.20 0.691 1584 8.67 0.343
Stone, concrete, tile 39 9.69 35 12.4
Number of rooms·
1 390 10.4 0.284 347 6.40 0.181
2 672 7.57 620 8.63
3+ 704 7.61 651 10.2
Number of beds
0–1 386 9.54 0.526 348 7.14 0.108
2 531 8.15 486 7.09
3+ 847 7.61 783 10.5
Electricity supply
Private meter 1169 8.33 0.782 1071 8.46 0.685
Other 595 7.94 546 9.20
Ownership of radio
No 314 10.8 0.077 279 10.2 0.379
Yes 1450 7.64 1338 8.41
Source of water
Public source 268 6.77 0.655 249 10.8 0.239
Shared tap 822 8.53 750 7.23
Own tap 674 8.34 618 9.84
* Analysis excludes seronegatives.
# Stratum of city ; inner high density (37 235/km2) and outer lower density (10 803/km2).
$ Migrant is a person born outside Addis Ababa, living in the city or a visitor at the time of the survey.
· Number of rooms in a household does not include kitchen or store rooms.
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measles, but a high proportion of individuals failed
to recognize or remember they had measles. The pre-
dictive value for a negative history of measles is
estimated to be only 25% (27/106). Furthermore,
we ﬁnd that of 1521 VE individuals reporting a his-
tory of measles illness, vaccination or both, 97 (6%)
were seronegative. Thus of the total of 148 sero-
negative children in this age range, 66% would not
have been identiﬁed as susceptible, suggesting that
historical information is unreliable in identifying
at-risk individuals.
Risk factors for measles seronegativity in VE children
In children aged 9 months to 14 years, absences of a
history of vaccination, or of ameasles-like illness, were
strong and independent predictors of seronegative
status (Tables 1, 2, Fig. 3a). Unvaccinated individuals
without a history of measles illness were roughly 10
times more likely to be seronegative than those vac-
cinated and who reported measles illness (25.6%;
95% CI 14.8–40.5 vs. 2.6%; 1.6–4.3). No other in-
dependently signiﬁcant associations were identiﬁed.
Interactions between age and each of sex, history of
measles, vaccination status, stratum and length of
residence were all found to be non-signiﬁcant.
Risk factors for low level antibody in VE children
In seropositive children aged 9 months to 14 years
a history of vaccination and absence of measles-like
illness were strongly associated with high prevalence
of low-level antibody status (Tables 1, 2, Fig. 3b) and
with lowGMT (Fig. 3c). We observed a 14-fold higher
prevalence of low positives in vaccinated individuals
without a history of measles illness (14.6%; 95% CI
11.9–17.7) than in individuals unvaccinated but with
measles-like illness (1.0%; 95% CI 0.1–7.5).
Measles illness history was available for the full age
range. The GMT measles antibody in seropositive
individuals with a history of symptomatic measles
remained roughly constant throughout the age range
at a level always higher than in those who reported no
measles history, other than age group 30–34 years. In
those without measles history there was a trend for
increase in GMT throughout childhood and a trend
for decrease in later life from 35–39 to 45–49 years.
Signiﬁcantly higher prevalence of low-level anti-
body was found in the outer city than the inner city
(13.2 and 5.44%, respectively) (Table 2). These results
cannot be attributed to diﬀerences in vaccine uptake
or in history of measles illness. No other independent
risk factors were identiﬁed and no signiﬁcant interac-
tions were identiﬁed with age.
Table 2. Multiple logistic regression models of potential factors associated
with measles seronegative status (<100 IU/l ) or low seropositive status
(100–255 IU/l ) in VE children in Addis Ababa, 1994
Variable
Seronegative status Low positive status*
Adj. OR 95% CI P Adj. OR 95% CI P
Age (years)
1–4 1.00 1.00
5–9 0.31 0.20–0.48 0.000 0.58 0.37–0.91 0.019
10–14 0.10 0.05–0.20 0.000 0.37 0.22–0.63 0.000
History of measles
Yes 1.00 1.00
No 3.82 2.29–6.39 0.000 2.29 1.55–3.37 0.000
Unknown 6.88 3.84–11.38 0.000 2.07 0.98–4.36 0.056
Vaccination status
Vaccine/card 1.00 1.00
Vaccine/history 1.82 1.08–3.07 0.025 1.01 0.63–1.62 0.973
Unvaccinated 4.30 1.96–9.43 0.001 0.35 0.17–0.71 0.005
Unknown 2.20 0.94–5.15 0.069 0.23 0.07–0.80 0.022
Stratum
Inner ni# 1.00
Outer 2.68 1.84–3.91 0.000
* Analysis excludes seronegatives.
# ni, not included in model.
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Measles incidence
Assuming a constant force of infection, Figure 4
shows the ﬁt of the catalytic infection model [eq. (1)]
to the observed proportions susceptible in ages 1–14
years, inclusive (open markers) or exclusive (ﬁlled
markers) of individuals with migrant status (n=233).
The force of infection l when migrants were excluded
was estimated to be 23%/year (95% CI 21–26%),
slightly higher than the value of 21%/year (19–24%)
inclusive of migrants. The eﬀect on the estimated
force of infection of using a reduced age range was
small (range in estimated l was 22–27%) and there
was no signiﬁcant improvement in model ﬁt allowing
a non-constant force of infection (with 2 or 3 age
groups). These results suggest that our estimate of the
force of infection in Addis 1994 of 23% is robust to
the main assumptions of time dependence both in
vaccine coverage and measles incidence. Given that
the proportion susceptible, x, in those aged less than
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Fig. 3. Age-speciﬁc proportions (a) seronegative (<100 IU/l), or (b) with low level antibody (100–255 IU/l, panel (b) sero-
positives only), and (c) GMT measles antibody by age (seropositives only), stratiﬁed by history of measles vaccination
(card or verbal) and illness. Dark bars : no illness, no vaccine (nMnV); dark grey bars : no illness, vaccine (nMV); light grey
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15 years is 9% and in those aged <5 years is 24%,
then the attack rate (i.e. l.x.1000) for each age class is
estimated at 21/1000 and 55/1000 per year, respect-
ively.
DISCUSSION
A large cross-sectional seroprevalence survey was con-
ducted in order to characterize measles epidemiology
and immunity in the population of Addis Ababa,
Ethiopia. The study employed a stratiﬁed cluster-
based household sample through which has been
generated precise and detailed seroepidemiological
information on measles in a developing country urban
setting experiencing moderately high measles vaccine
coverage. The sample was representative, insofar as
the socio-demographic structure of the sample holds
remarkably well with that recorded in the 1994 cen-
sus of Addis Ababa [13, 15]. There are few previous
reports of antibody prevalence from such large and
representative sample surveys [3, 4] and particularly
for Africa.
The ELISA kit used to quantify measles speciﬁc
antibody levels has been found to compare well
against other commercially available ELISAs and to
be suited to quantitative measurement [21]. Report-
ing of quantitative antibody measurement in stan-
dard international units is important for comparison
between studies, although the use of diﬀerent assay
formats (e.g. ELISA, haemagglutination inhibtion,
and antibody neutralization) in diﬀerent studies
argues for caution in this process. The threshold for
seronegativity of 100 IU/l is similar to some pre-
vious, reports [3, 4, 10, 21], though not all [7]. The
cut-oﬀ level for low positives of 255 IU/l follows that
previously reported [4]. Levels of 500 and 1000 have
been suggested as deﬁning the cut-oﬀ for protection
against infection and clinical measles [9]. There is
considerable variation within the literature on where
these boundaries lie and on the relationship between
speciﬁc-antibody levels and protection from infection
and disease. The material has been reviewed elsewhere
[4, 8–10], and further interpretation is beyond the
scope of this paper.
Based mostly on verbal history (Fig. 2) our results
indicate that measles vaccine coverage has been
moderately high and relatively stable at about 80%
in the population of Addis Ababa for over a decade.
This is consistent with the available oﬃcial records.
However, we obtain a minimum estimate for primary
vaccine failure rate of 21% (95% CI 12–34) from
seronegative children 9–23 months old with vacci-
nation history (some of these children may have
antibody induced by natural infection). This suggests
a potential problem in the eﬀectiveness in delivery of
measles vaccine in Addis Ababa. Higher coverage
of lifelong resident children compared to migrants
reﬂects known diﬀerences between urban and rural
Ethiopia [26].
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Highest proportions seronegative (<100 IU/l) were
identiﬁed in infants less than 9 months (66%) and
children aged 1–3 years (25%) and 4–6 years (13%).
In ages 7 years and upwards the proportion with de-
tectable antibody was in excess of 93%, rising to 99%
in adults 15–49. Statistics for Addis Ababa suggest a
population under demographic transition; the birth
rate has markedly declined over the past 30 years [13].
In 1994, 0–4 year olds represented only 8% of the
total population and the largest proportion (16%)
was in the age group 15–19 years [16]. Given this age
structure there is in fact a fairly even distribution
of numbers of susceptibles throughout the child age
range. Analysis of the change with age in proportion
seronegative using a catalytic infection model yields
a most likely estimate of measles incidence rate of
around 22–23 per 100 susceptibles per annum in chil-
dren 1–14 years of age, indicative of continued high
measles transmission. This is despite moderately high
measles vaccination levels. Unfortunately there are no
reliable reported statistics for measles notiﬁcations
in Ethiopia. Measles seronegativity was strongly and
independently associated with an absence of a history
of vaccination or of measles illness. Other than age,
no other independent risk factors for seronegativity
were identiﬁed.
The analysis of antibody levels concentrates on
seropositive individuals falling into the low level cat-
egory (100–255) for whom there is some evidence of
susceptibility to either mild clinical or sub-clinical
reinfection [8, 9]. A signiﬁcant proportion (8%) of
children (aged <15 years) were identiﬁed as having
low-level antibody (100–255 IU/l). Stratiﬁed analysis
of seropositives conﬁrms a strong independent as-
sociation between a history of measles vaccination
and low measles antibody level. The observed decline
in the proportion with low level antibody over the
childhood age range is predominantly associated with
an increase in GMT in vaccinated seropositives, and
may arise from the boosting of low-level antibody by
exposure to continued circulating measles virus. Such
a decrease in the prevalence of low-level seropositivity
was not observed in a study of children in Bolivia,
perhaps reﬂecting more eﬀective control of measles
virus in the South American population [3]. Absence
of a history of measles illness was also strongly as-
sociated with low-level seropositivity. An association
between measles history and high antibody level was
previously reported for children in a study in Bolivia
[3]. Our study identiﬁed a strong independent associ-
ation between low level antibody and residence in the
outer less densely populated region of the city. It is
possible that this is the result of less boosting of anti-
bodies by exposure to measles, associated with lower
population density.
We attach little importance directly to the esti-
mated proportion with low antibody level of between
100–255 IU/l. Instead, we highlight that this result
adds to the reports of high proportions of individ-
uals with low positive antibody levels in vaccinated
populations [3, 4, 8], for whom a role in continued
transmission of measles, though unlikely, cannot be
discounted [8]. The inference from this and other
studies [8, 27] is that higher levels of vaccination
(single dose) and an accompanying decrease in the
boosting eﬀect of viral exposure are likely to further
increase the proportion with low-level antibody. An
emerging population of vaccinated low positive
individuals may be an issue in considering the merits
of supplementary doses of measles vaccine to boost
immunity.
In late 1998 mass measles campaigns were conduc-
ted for the ﬁrst time in Ethiopia in nine selected urban
cities, including Addis Ababa, targeting children aged
9–59 months old, as part of the accelerated measles
control strategy in Ethiopia [18]. As is usual in cam-
paigns, measles vaccine was oﬀered irrespective of
past measles vaccination or illness. The ﬁndings of
the current study, as previously [3], show that his-
torical information on measles vaccination and ill-
ness is of little use in identifying seronegatives, and
would not support a more targeted approach to
campaign vaccination. Our survey in 1994 indicates
20% seronegative and 17% low seropositive in 9- to
59-month-old children. Together with evidence for
continued high rate of transmission in Addis (despite
moderately high level vaccination), these data justify
the need for the accelerated control eﬀort im-
plemented in Addis Ababa. However, although the
survey indicated only 5% seronegative and 7% low
positive in the 5–14 years age range, this age group
comprises 24% of the total population compared to
only 8% in those<5 years. Targeting children under
5 is appropriate when the aim is to reduce measles-
associated mortality. Inclusion of older children in
campaigns, as in other countries [28], could have a
greater impact on reducing the numbers of suscep-
tibles, and consequently of cases, and would be
necessary if the immunization programme aimed to
interrupt transmission [29]. Our conclusion is that the
beneﬁts of the campaign are likely to be short lived
in the absence of increased routine immunization
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coverage at age 9 months or repeated campaigns [30].
Careful consideration should now be given to the
prevention of future epidemics, the like of which have
been observed elsewhere following campaign inter-
vention [31, 32]. The control of measles in Addis
Ababa has wider implications for measles persistence
in Ethiopia given its large size (roughly 1/25 of the
total population). Further antibody prevalence sur-
veys to assess the impact of the recent campaigns
would be beneﬁcial in developing immunization pol-
icy. Oral-ﬂuid methods have been identiﬁed as useful
in this process [12, 33–35].
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